Table 1.

Baseline characteristics of patients with colorectal cancer.

Characteristic	Total	Control group	CIK group	P
No. of patients	122	62	60
Sex				0.536
Male	78	38	40
Female	44	24	20
Age (years)				0.606
≥ 60	34	16	18
< 60	88	46	42
Primary tumor				0.498
Rectum	43	24	19
Left-sided colon	46	24	22
Right-sided colon	33	14	19
Histology				1.000a
Well differentiated	9	5	4
Moderate differentiated	84	42	42
Poorly differentiated	29	15	14
T stage				0.597a
T1 + T2	8	3	5
T3	65	32	33
T4	49	27	22
N stage				0.186
N0	33	20	13
N1	65	28	37
N2	24	14	10
TNM stageb				0.021a
II	32	21	11
III	86	41	45
IV	4	0	4
Tumor size (cm)				0.161
< 4	34	17	17
≥ 4	38	15	23
Missing data	50	30	20
Neural invasion				0.520
Absent	91	48	43
Present	15	8	7
Missing data	16	6	10
Venous invasion				0.452
Absent	78	40	38
Present	28	16	12
Missing data	16	6	10
MMR status				0.519a
dMMR	3	1	2
pMMR	34	15	19
Missing data	85	46	39
Chemotherapy regimen				0.371a
FOLFOX	31	19	12
CAPOX	81	39	42
Capecitabine	10	4	6
Duration of chemotherapy				0.252
> 20 weeks	73	34	39
< 20 weeks	49	28	21
Adjuvant radiotherapy				0.504
Yes	12	5	7
No	110	57	53
Neoadjuvant chemotherapy				0.145
Yes	18	12	6
No	104	50	54
Neoadjuvant radiotherapy				0.373
Yes	11	7	4
No	111	55	56

CIK, cytokine-induced killer cell. CAPOX, Capecitabine + Oxaliplatin. FOLFOX, Oxaliplatin + 5-fluorouracil. MMR, mismatch repair; dMMR, MMR-defcient; pMMR, MMR-profcient.

a, Fisher’s exact test. b, According to the 8th edition of the American Joint Committee on Cancer staging system.